News Brief
World's First Chikungunya Vaccine Gets Green Light From US Drug Regulator
US health authorities have granted approval for the world's first chikungunya vaccine.
In a positive development, US health authorities have granted approval for the world's first chikungunya vaccine, Ixchiq, developed by Europe's Valneva.
The vaccine, aimed at individuals aged 18 and over at an increased risk of exposure, has been identified by the Food and Drug Administration (FDA) as a crucial step in combating the virus, which it labels as "an emerging global health threat", as reported by NDTV.
Chikungunya, transmitted by infected mosquitoes, induces symptoms such as fever and severe joint pain, with the virus predominantly affecting tropical and subtropical regions in Africa, southeast Asia, and parts of the Americas.
The FDA noted the virus's expanding geographical reach, reporting over 5 million cases in the past 15 years.
The vaccine's approval is anticipated to accelerate its deployment in areas with a high prevalence of the disease.
Administered in a single dose, Ixchiq employs a live, weakened version of the chikungunya virus, aligning with the standard approach for vaccine development.
Two clinical trials involving 3,500 participants in North America demonstrated common side effects such as headache, fatigue, muscle and joint pain, fever, and nausea.
While serious reactions were reported in 1.6 per cent of Ixchiq recipients during the trials, with two individuals requiring hospitalization.
The FDA hails this approval as a critical advancement in addressing an unmet medical need for a potentially debilitating disease with limited treatment options.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
